As pricing pressures continue to increase in Europe, pharma companies are starting to shrink their European footprint with smaller commercial organizations and a narrower focus on key products or specialty areas.

The sales numbers tell the story: Across 10 pharma companies that have broken out their numbers, 2012 European drug sales were down $10.1 billion (11%) compared to 2011.